Skip to main
ABEO
ABEO logo

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 73%
Buy 20%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics Inc. is positioned favorably for commercialization of its key therapy, pz-cel, with a potential pathway to sustainable profitability contingent on its market uptake in the U.S. The company has demonstrated statistically significant improvements in clinical outcomes, which could support demand and reimbursement prospects. Additionally, plans to onboard high-volume treatment centers and anticipated access to significant non-dilutive capital within the next year enhance the operational capacity for pz-cel's launch, indicating a robust foundation for future growth.

Bears say

Abeona Therapeutics reported a net loss of $0.63 per share in the third quarter of 2024, with full-year 2024 net loss estimates widening to $1.62 per share, significantly higher than the initial forecast of $0.40 per share. The company faces multiple risks, including potential FDA rejection of its resubmitted biologics license application for pz-cel and uncertainty regarding market uptake in the U.S., which could adversely affect revenue and future profitability. Additionally, the substantial non-cash loss of $15.2 million related to changes in the fair value of liabilities further exacerbates concerns regarding the company's financial stability and future capital position, contributing to a negative outlook on its stock.

Abeona Therapeutics (ABEO) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 20% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 15 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.